{rfName}

Indexed in

License and use

Citations

172

Altmetrics

Grant support

This work was supported by Grants FIS 07/1024, FIS 08/1195, and FIS 08/0733. Centro de Investigacion Biomedica en Red de Diabetes y Enfermedades Metabolicas Asociadas is an initiative of the Instituto de Salud Carlos III (CB07/08/0012) (to V.C.-M., X.E., J.M.G., M.M., M.R.C., L.G., and J.V.). M.R.C. is supported by a fellowship (CP06/00119) from the Fondo de Investigacion Sanitaria. X. E. is supported by a fellowship from the Juan de la Cierva program and Grant JDCI20071020.

Analysis of institutional authors

Ceperuelo-Mallafre, V.AuthorNaf Cortés, Silvia DanielaAuthorEscote, X.AuthorMiranda, M.AuthorChacon, M. R.AuthorGallart, L.AuthorGutiérrez, C.AuthorVendrell, J.Corresponding Author

Share

February 10, 2020
Publications
>
Article
No

Circulating and Adipose Tissue Gene Expression of Zinc-alpha 2-Glycoprotein in Obesity: Its Relationship with Adipokine and Lipolytic Gene Markers in Subcutaneous and Visceral Fat

Publicated to:Journal Of Clinical Endocrinology & Metabolism. 94 (12): 5062-5069 - 2009-12-01 94(12), DOI: 10.1210/jc.2009-0764

Authors: Caubet, E; Gomez, J M; Gonzalez-Clemente, J M; Vendrell, J

Affiliations

Hosp Sta Tecla, Diabet Surg Serv, Tarragona 43007, Spain - Author
Univ Autonoma Barcelona, Diabet Endocrinol & Nutr Dept, Hosp Sabadell, Inst Univ Parc Tauli, Sabadell 08208, Spain - Author
Univ Hosp Bellvitge, Endocrinol & Diabet Unit, Barcelona 08907, Spain - Author
Univ Rovira & Virgili, Univ Hosp Tarragona Joan XXIII, Endocrinol & Nutr Unit, IISPV,Res Dept,Pere Virgili Inst, Tarragona 43007, Spain - Author
See more

Abstract

Context: Zinc-alpha 2-glycoprotein (ZAG) is a soluble protein similar to the class I major histocompatibility complex heavy chain, which has been implicated in lipid catabolism. We hypothesized that ZAG mRNA expression in adipose tissue may be linked with lipolytic and adipokine gene expression and have a close relationship with clinical phenotype. Objectives: The objective of the study was to analyze ZAG gene expression in human adipose tissue from lean and obese subjects. ZAG circulating plasma levels and its relationship with cardiometabolic risk factors were also studied. Design: Seventy-three Caucasian (43 male and 30 female) subjects were included. Plasma and adipose tissue [sc (SAT) and visceral (VAT)] from the same patient were studied. mRNA of PPAR gamma, hormone-sensitive lipase (HSL), adipose triglyceride lipase, adiponectin, omentin, visfatin, and ZAG were quantified. Plasma concentrations of ZAG were determined with ELISA. Results: ZAG plasma levels showed a negative correlation with insulin (r = -0.39; P = 0.008) and the homeostasis model assessment for insulin resistance index (r = -0.36; P = 0.016). No differences in ZAG circulating levels according to body mass index classification were observed. ZAG expression in SAT was significantly reduced in overweight and obese individuals compared with lean subjects (P < 0.001 and P = 0.007, respectively). ZAG mRNA expression in both SAT and VAT depots were negatively correlated with many clinical and metabolic cardiovascular risk factors. After multiple linear regression analysis, SAT ZAG was mainly predicted by adiponectin mRNA expression (B = 0.993; P < 0.0001) and plasma triglyceride levels (B = -0.565; P = 0.006). VAT ZAG expression was predicted by adiponectin expression (B = 0.449; P < 0.0001), and HSL VAT expression (B = 0.180; P = 0.023). Conclusions: The present study provides evidence of a role of ZAG gene in adipose tissue metabolism, with a close association with adiponectin gene expression in sc and visceral fat. (J Clin Endocrinol Metab 94: 5062-5069, 2009)

Keywords

Hormone-sensitive lipaseLipid-mobilizing factorModelZinc-alpha(2)-glycoprotein

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Journal Of Clinical Endocrinology & Metabolism due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2009, it was in position 10/105, thus managing to position itself as a Q1 (Primer Cuartil), in the category Endocrinology & Metabolism.

From a relative perspective, and based on the normalized impact indicator calculated from the Field Citation Ratio (FCR) of the Dimensions source, it yields a value of: 10.22, which indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: Dimensions Oct 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-10-29, the following number of citations:

  • WoS: 63
  • Scopus: 71
  • Europe PMC: 33

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-10-29:

  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 55 (PlumX).

Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (Ceperuelo Mallafré, Maria Victoria) and Last Author (Vendrell Ortega, Juan José).

the author responsible for correspondence tasks has been Vendrell Ortega, Juan José.